University of Heidelberg
Faculty of Medicine Mannheim
University Hospital Mannheim
These pages are still under constructions and will be available soon! Please check again later!

If you have questions concerning a specific publication please use this form with subject 'information about publications' and giving the full citation in the message body.

Collaborate Research Projects
Home > Publications > Abstract >

Low-grade astrocytoma: treatment with conventionally fractionated stereotactic radiation therapy

M. van Kampen, R. Engenhart-Cabillic, J. Debus, T. Hess, L. Schad and M. Wannenmacher

Radiology, 201 (1), pp.275-278

PURPOSE: To assess the efficacy of fractionated stereotactic radiation therapy for low-grade astrocytoma in terms of improvements to therapeutic ratio, patient survival, and quality of life. MATERIALS AND METHODS: Since 1987, 32 patients with inoperable grade II astrocytoma were irradiated. Stereotactic radiation therapy was given only to patients with progressive symptoms. The mean total dose applied was 59.8 Gy (range, 54.0-65.0 Gy). RESULTS: Four years after therapy, the overall survival rate calculated with Kaplan-Meier analysis was 76\%. Median progression-free survival was 48 months. On the basis of clinical symptoms, 91\% (29 of 32) of patients showed improvement or stable disease after stereotactic radiation therapy. Eleven local failures were observed, 10 of which were within the planning target volume; one patient had a continuously enlarging mass. Acute toxic effects of radiation did not exceed grade II of the World Health Organization classification. Two patients developed reversible contrast enhancement without clinical symptoms on MR images within 1 year after stereotactic radiation therapy. CONCLUSION: Stereotactic radiation therapy for grade II astrocytoma appears to improve patients' quality of life or stabilize disease and is not correlated with marginal misses.

Contact: Dr. Frank Zöllner last modified: 21.09.2020
to top of page